Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, was featured in a recent equity research report. The coverage, initiated by Ladenburg Thalmann & Co. Inc., highlights Tryp Therapeutics’ efforts to reset the treatment of various disorders through the novel dosing of formulations of … Continue reading InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Equity Research Report